Study of Treatments for Atrial Fibrillation with Atrial Functional Mitral Regurgitation Comparing Catheter Ablation and Drug Therapy Effects

What this Trial Is About

Atrial fibrillation causes the atria to lose their normal contraction ability, leading to blood pooling and enlargement of the left atrium. This enlargement can cause dilation of the mitral valve area and mitral regurgitation, called atrial functional mitral regurgitation AFMR. Researchers are studying how catheter ablation compared to regular drug treatment affects mitral regurgitation in patients with atrial fibrillation combined with AFMR in this prospective, multicenter cohort study. Participants diagnosed with symptomatic paroxysmal atrial fibrillation and moderate to severe mitral regurgitation with normal heart function are enrolled. They are assigned either to receive catheter ablation using pulsed field technology or regular drug therapy based on clinical judgment or personal preference. Follow-up visits to assess changes are scheduled at 3, 6, and 12 months after enrollment. During the study, patients will undergo echocardiography to measure mitral regurgitation severity, left ventricular and atrial function, and arrhythmia recurrence. Researchers will also monitor procedure success and safety events. Quality of life and heart failure-related events are tracked to evaluate the impact of treatments. The entire study period includes multiple follow-ups up to one year after enrollment.

Study of Atrial Fibrillation Combined with Atrial Functional Mitral Regurgitation